Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Mineralys Therapeutics to Participate in the Guggenheim Securities 6th Annual Biotechnology Conference | ||||||||||||
By: GlobeNewswire - 29 Jan 2024 | Back to overview list |
|||||||||||
RADNOR, Pa., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced that Chief Executive Officer Jon Congleton will be participating in a fireside chat at the Guggenheim Securities 6th Annual Biotechnology Conference, being held in New York City on February 7-8, 2024.
A live webcast of the fireside chat can be accessed under “News and Events” on the Investor Relations section of the Mineralys website at www.mineralystx.com. A replay of the fireside chat will be available on the Company’s website for approximately 90 days. About Mineralys Therapeutics Contact: Investor Relations Media Relations |
||||||||||||
|
||||||||||||
Copyright 2024 GlobeNewswire | Back to overview list |